 Carlton Barnett
Concepts (278)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colonic Neoplasms | 5 | 2020 | 254 | 1.960 |
Why?
| | Pancreatic Neoplasms | 10 | 2013 | 935 | 1.800 |
Why?
| | Intercellular Adhesion Molecule-1 | 7 | 2013 | 139 | 1.550 |
Why?
| | Adenocarcinoma | 8 | 2020 | 938 | 1.440 |
Why?
| | Erythrocyte Transfusion | 6 | 2013 | 193 | 1.380 |
Why?
| | Liver Neoplasms | 6 | 2020 | 785 | 1.270 |
Why?
| | Neutrophils | 13 | 2017 | 1236 | 1.220 |
Why?
| | Plasma | 4 | 2013 | 212 | 1.050 |
Why?
| | Hyperthermia, Induced | 3 | 2021 | 116 | 0.870 |
Why?
| | Cytokines | 4 | 2013 | 2084 | 0.690 |
Why?
| | Burns, Electric | 1 | 2020 | 26 | 0.680 |
Why?
| | Tumor Microenvironment | 3 | 2020 | 672 | 0.670 |
Why?
| | Microwaves | 2 | 2019 | 37 | 0.670 |
Why?
| | Transfusion Reaction | 2 | 2010 | 45 | 0.660 |
Why?
| | Blood Preservation | 2 | 2012 | 283 | 0.540 |
Why?
| | Kidney Neoplasms | 1 | 2021 | 401 | 0.530 |
Why?
| | Surgical Flaps | 2 | 2016 | 130 | 0.530 |
Why?
| | Liver | 2 | 2020 | 1940 | 0.530 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2021 | 1058 | 0.520 |
Why?
| | Ileocecal Valve | 1 | 2016 | 4 | 0.520 |
Why?
| | Macrophages | 4 | 2013 | 1544 | 0.510 |
Why?
| | Organ Sparing Treatments | 1 | 2016 | 34 | 0.500 |
Why?
| | Colectomy | 1 | 2016 | 100 | 0.480 |
Why?
| | Pancreaticojejunostomy | 1 | 2015 | 8 | 0.470 |
Why?
| | Duodenum | 1 | 2015 | 77 | 0.450 |
Why?
| | Multiple Organ Failure | 5 | 2011 | 127 | 0.430 |
Why?
| | Blood Substitutes | 1 | 2013 | 27 | 0.400 |
Why?
| | Disease Progression | 6 | 2020 | 2750 | 0.390 |
Why?
| | Crohn Disease | 1 | 2016 | 243 | 0.390 |
Why?
| | Pancreas | 1 | 2015 | 329 | 0.390 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2020 | 543 | 0.380 |
Why?
| | Neoplasm Metastasis | 3 | 2013 | 657 | 0.380 |
Why?
| | Hematocrit | 1 | 2012 | 96 | 0.370 |
Why?
| | Blood Loss, Surgical | 2 | 2010 | 100 | 0.370 |
Why?
| | Cell Line, Tumor | 6 | 2020 | 3405 | 0.350 |
Why?
| | Mice | 12 | 2020 | 17757 | 0.340 |
Why?
| | Hemoglobins | 1 | 2013 | 353 | 0.340 |
Why?
| | Hernia, Abdominal | 1 | 2010 | 6 | 0.340 |
Why?
| | Epigenesis, Genetic | 1 | 2015 | 657 | 0.330 |
Why?
| | Peritoneum | 1 | 2010 | 43 | 0.330 |
Why?
| | Osteomyelitis | 2 | 2009 | 131 | 0.330 |
Why?
| | Surgical Mesh | 1 | 2010 | 47 | 0.330 |
Why?
| | Blood Component Transfusion | 1 | 2010 | 84 | 0.320 |
Why?
| | Interleukin-6 | 5 | 1996 | 778 | 0.320 |
Why?
| | Hemipelvectomy | 1 | 2008 | 2 | 0.310 |
Why?
| | Hepatectomy | 2 | 2008 | 249 | 0.300 |
Why?
| | Pancreaticoduodenectomy | 1 | 2010 | 163 | 0.300 |
Why?
| | Blood Platelets | 2 | 2012 | 406 | 0.300 |
Why?
| | Pressure Ulcer | 1 | 2008 | 46 | 0.290 |
Why?
| | Fires | 2 | 2019 | 89 | 0.290 |
Why?
| | Neoplasms | 2 | 2017 | 2643 | 0.290 |
Why?
| | Operating Rooms | 2 | 2019 | 123 | 0.280 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2010 | 209 | 0.280 |
Why?
| | Mice, Inbred C57BL | 5 | 2020 | 5749 | 0.280 |
Why?
| | Colorectal Neoplasms | 1 | 2015 | 791 | 0.280 |
Why?
| | Platelet Transfusion | 1 | 2008 | 67 | 0.270 |
Why?
| | Animals | 17 | 2020 | 36847 | 0.270 |
Why?
| | Critical Care | 1 | 2012 | 583 | 0.260 |
Why?
| | Neovascularization, Pathologic | 1 | 2008 | 301 | 0.250 |
Why?
| | Laparoscopy | 2 | 2010 | 464 | 0.250 |
Why?
| | Critical Illness | 1 | 2012 | 804 | 0.250 |
Why?
| | Neoplasm Invasiveness | 4 | 2013 | 507 | 0.240 |
Why?
| | Teaching | 1 | 2008 | 224 | 0.240 |
Why?
| | Macrophage Activation | 2 | 2020 | 201 | 0.240 |
Why?
| | Sex Characteristics | 1 | 2010 | 759 | 0.230 |
Why?
| | Humans | 41 | 2021 | 136765 | 0.220 |
Why?
| | Superoxides | 5 | 1998 | 202 | 0.210 |
Why?
| | Disease Models, Animal | 4 | 2020 | 4282 | 0.200 |
Why?
| | Adrenal Gland Neoplasms | 2 | 2001 | 89 | 0.200 |
Why?
| | Platelet Activating Factor | 4 | 1999 | 76 | 0.200 |
Why?
| | Wounds and Injuries | 3 | 2012 | 755 | 0.190 |
Why?
| | Neoplasm Transplantation | 2 | 2020 | 257 | 0.180 |
Why?
| | Phospholipases A | 1 | 2001 | 102 | 0.180 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2001 | 361 | 0.180 |
Why?
| | Catheter Ablation | 2 | 2001 | 349 | 0.170 |
Why?
| | Arginase | 1 | 2020 | 32 | 0.170 |
Why?
| | Leukocyte Elastase | 2 | 1997 | 76 | 0.170 |
Why?
| | Perioperative Care | 1 | 2021 | 178 | 0.160 |
Why?
| | Immunocompetence | 1 | 2019 | 42 | 0.160 |
Why?
| | Aftercare | 1 | 2021 | 207 | 0.160 |
Why?
| | Electrosurgery | 1 | 2019 | 43 | 0.160 |
Why?
| | Thoracic Injuries | 1 | 1999 | 55 | 0.160 |
Why?
| | Dermatologic Surgical Procedures | 1 | 2019 | 20 | 0.160 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 278 | 0.150 |
Why?
| | Clinical Decision-Making | 1 | 2021 | 319 | 0.150 |
Why?
| | Ethanol | 2 | 2019 | 606 | 0.150 |
Why?
| | Wearable Electronic Devices | 1 | 2019 | 53 | 0.150 |
Why?
| | CD18 Antigens | 1 | 1998 | 26 | 0.150 |
Why?
| | Smoke | 1 | 2019 | 140 | 0.150 |
Why?
| | Apoptosis | 3 | 1996 | 2551 | 0.150 |
Why?
| | Endopeptidases | 1 | 1998 | 90 | 0.140 |
Why?
| | Lymphatic Metastasis | 2 | 2010 | 351 | 0.140 |
Why?
| | Internship and Residency | 1 | 2008 | 1132 | 0.140 |
Why?
| | Injury Severity Score | 3 | 2015 | 521 | 0.140 |
Why?
| | Pancreatic Elastase | 2 | 1999 | 58 | 0.140 |
Why?
| | Peritoneal Neoplasms | 2 | 2010 | 93 | 0.130 |
Why?
| | Carbon Dioxide | 1 | 2019 | 267 | 0.130 |
Why?
| | Isoproterenol | 1 | 1997 | 113 | 0.130 |
Why?
| | Sex Factors | 2 | 2015 | 2060 | 0.130 |
Why?
| | Hemostasis, Surgical | 2 | 2008 | 22 | 0.130 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1997 | 127 | 0.130 |
Why?
| | Inflammation Mediators | 1 | 1999 | 513 | 0.130 |
Why?
| | Adrenergic beta-Agonists | 1 | 1997 | 133 | 0.130 |
Why?
| | Cell Death | 1 | 1998 | 372 | 0.130 |
Why?
| | Surgical Procedures, Operative | 1 | 2019 | 258 | 0.130 |
Why?
| | Patient Care Team | 1 | 2021 | 626 | 0.130 |
Why?
| | General Surgery | 2 | 2009 | 169 | 0.130 |
Why?
| | Female | 17 | 2019 | 72795 | 0.130 |
Why?
| | Calcium | 2 | 2001 | 1197 | 0.120 |
Why?
| | Breast Neoplasms | 1 | 2008 | 2234 | 0.120 |
Why?
| | Interleukin-8 | 1 | 1996 | 268 | 0.120 |
Why?
| | Chimerism | 1 | 2015 | 31 | 0.120 |
Why?
| | Erythrocytes | 2 | 2012 | 699 | 0.120 |
Why?
| | Recovery of Function | 1 | 2019 | 652 | 0.120 |
Why?
| | Down-Regulation | 2 | 2013 | 656 | 0.120 |
Why?
| | Parity | 1 | 2015 | 125 | 0.110 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2008 | 382 | 0.110 |
Why?
| | Patient Discharge | 1 | 2021 | 894 | 0.110 |
Why?
| | Skin | 1 | 2019 | 751 | 0.110 |
Why?
| | Male | 16 | 2019 | 67311 | 0.110 |
Why?
| | Treatment Outcome | 4 | 2019 | 10745 | 0.100 |
Why?
| | Adult | 12 | 2016 | 37631 | 0.100 |
Why?
| | In Vitro Techniques | 2 | 2010 | 1089 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2013 | 37 | 0.100 |
Why?
| | Chemokine CCL5 | 1 | 2013 | 43 | 0.100 |
Why?
| | Physicians | 1 | 2021 | 907 | 0.100 |
Why?
| | Protein Array Analysis | 1 | 2013 | 57 | 0.100 |
Why?
| | Epidermal Growth Factor | 1 | 2013 | 175 | 0.100 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2012 | 1242 | 0.100 |
Why?
| | Survival Rate | 2 | 2015 | 1963 | 0.100 |
Why?
| | Tumor Cells, Cultured | 2 | 2012 | 953 | 0.090 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2012 | 91 | 0.090 |
Why?
| | Stromal Cells | 1 | 2012 | 112 | 0.090 |
Why?
| | Chemokine CCL2 | 1 | 2012 | 115 | 0.090 |
Why?
| | RNA, Small Interfering | 1 | 2013 | 622 | 0.090 |
Why?
| | Neoplasms, Experimental | 1 | 2012 | 176 | 0.090 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 530 | 0.090 |
Why?
| | Perioperative Period | 1 | 2010 | 56 | 0.080 |
Why?
| | Blood Transfusion, Autologous | 1 | 2010 | 17 | 0.080 |
Why?
| | Injections, Intravenous | 1 | 2010 | 207 | 0.080 |
Why?
| | Analysis of Variance | 1 | 2013 | 1316 | 0.080 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2010 | 80 | 0.080 |
Why?
| | Linear Models | 1 | 2012 | 846 | 0.080 |
Why?
| | Immunomodulation | 1 | 2010 | 98 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 851 | 0.080 |
Why?
| | Tetradecanoylphorbol Acetate | 3 | 1999 | 150 | 0.080 |
Why?
| | Academic Medical Centers | 1 | 2012 | 504 | 0.080 |
Why?
| | Thrombocytopenia | 1 | 2011 | 198 | 0.080 |
Why?
| | DNA Primers | 1 | 2010 | 514 | 0.080 |
Why?
| | Signal Transduction | 3 | 2020 | 5076 | 0.070 |
Why?
| | Angiogenesis Inducing Agents | 1 | 2008 | 24 | 0.070 |
Why?
| | Ligation | 1 | 2008 | 87 | 0.070 |
Why?
| | Hepatic Veins | 1 | 2008 | 33 | 0.070 |
Why?
| | Hepatic Artery | 1 | 2008 | 61 | 0.070 |
Why?
| | Cholecystectomy | 1 | 2008 | 60 | 0.070 |
Why?
| | Pelvic Bones | 1 | 2009 | 128 | 0.070 |
Why?
| | RNA, Messenger | 2 | 2013 | 2831 | 0.070 |
Why?
| | Time Factors | 4 | 2012 | 6808 | 0.070 |
Why?
| | CHO Cells | 2 | 1998 | 161 | 0.070 |
Why?
| | Aged | 7 | 2019 | 23794 | 0.070 |
Why?
| | Cricetinae | 2 | 1998 | 289 | 0.070 |
Why?
| | Swine | 2 | 2019 | 773 | 0.070 |
Why?
| | Middle Aged | 9 | 2019 | 33228 | 0.060 |
Why?
| | Base Sequence | 1 | 2010 | 2179 | 0.060 |
Why?
| | Safety | 1 | 2008 | 338 | 0.060 |
Why?
| | Cell Movement | 1 | 2010 | 968 | 0.060 |
Why?
| | Body Weight | 1 | 2010 | 985 | 0.060 |
Why?
| | Preoperative Care | 1 | 2008 | 356 | 0.060 |
Why?
| | Education, Medical | 1 | 2009 | 260 | 0.060 |
Why?
| | Surgical Stapling | 1 | 2005 | 14 | 0.060 |
Why?
| | Immediate-Early Proteins | 1 | 2005 | 49 | 0.060 |
Why?
| | Follow-Up Studies | 3 | 2009 | 5106 | 0.060 |
Why?
| | Prognosis | 2 | 2010 | 4013 | 0.060 |
Why?
| | Cytosol | 2 | 2001 | 226 | 0.050 |
Why?
| | Mice, Knockout | 1 | 2010 | 3008 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2010 | 2475 | 0.050 |
Why?
| | Endothelium, Vascular | 2 | 2001 | 926 | 0.050 |
Why?
| | Retrospective Studies | 6 | 2021 | 15504 | 0.050 |
Why?
| | Adrenalectomy | 1 | 2001 | 68 | 0.050 |
Why?
| | Cells, Cultured | 4 | 1997 | 4191 | 0.050 |
Why?
| | Injections, Intralesional | 1 | 2001 | 34 | 0.050 |
Why?
| | Egtazic Acid | 1 | 2001 | 40 | 0.050 |
Why?
| | Umbilical Veins | 1 | 2001 | 61 | 0.050 |
Why?
| | Chelating Agents | 1 | 2001 | 75 | 0.040 |
Why?
| | Cryosurgery | 1 | 2001 | 59 | 0.040 |
Why?
| | Pilot Projects | 2 | 2019 | 1692 | 0.040 |
Why?
| | Risk Factors | 5 | 2021 | 10325 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2012 | 5423 | 0.040 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2001 | 91 | 0.040 |
Why?
| | Hospitals, Veterans | 1 | 2021 | 249 | 0.040 |
Why?
| | Sialoglycoproteins | 1 | 1999 | 159 | 0.040 |
Why?
| | 2-Propanol | 1 | 2019 | 20 | 0.040 |
Why?
| | Chlorhexidine | 1 | 2019 | 23 | 0.040 |
Why?
| | Prospective Studies | 3 | 2021 | 7572 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 1999 | 164 | 0.040 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 1999 | 93 | 0.040 |
Why?
| | Receptors, Interleukin-1 | 1 | 1999 | 216 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2005 | 1396 | 0.040 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 1999 | 253 | 0.040 |
Why?
| | CD11 Antigens | 1 | 1998 | 30 | 0.040 |
Why?
| | Up-Regulation | 1 | 2001 | 844 | 0.040 |
Why?
| | Postoperative Period | 1 | 2019 | 342 | 0.040 |
Why?
| | Models, Animal | 1 | 2019 | 384 | 0.040 |
Why?
| | Equipment Design | 1 | 2019 | 521 | 0.040 |
Why?
| | Microscopy, Electron | 1 | 1998 | 432 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2001 | 886 | 0.030 |
Why?
| | N-Formylmethionine Leucyl-Phenylalanine | 1 | 1997 | 54 | 0.030 |
Why?
| | Protease Inhibitors | 1 | 1998 | 107 | 0.030 |
Why?
| | Colforsin | 1 | 1997 | 53 | 0.030 |
Why?
| | Cross-Linking Reagents | 1 | 1998 | 211 | 0.030 |
Why?
| | United States Department of Veterans Affairs | 1 | 2021 | 674 | 0.030 |
Why?
| | Cardiopulmonary Bypass | 1 | 1999 | 209 | 0.030 |
Why?
| | Cell Adhesion | 1 | 1998 | 466 | 0.030 |
Why?
| | Walking | 1 | 2021 | 523 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 3 | 2001 | 2667 | 0.030 |
Why?
| | Ultrafiltration | 1 | 1996 | 28 | 0.030 |
Why?
| | Chromatography, Affinity | 1 | 1996 | 88 | 0.030 |
Why?
| | Risk Assessment | 2 | 2021 | 3432 | 0.030 |
Why?
| | Transfection | 1 | 1998 | 941 | 0.030 |
Why?
| | Awards and Prizes | 1 | 1996 | 67 | 0.030 |
Why?
| | Patient Readmission | 1 | 2021 | 694 | 0.030 |
Why?
| | Cell Line | 1 | 2001 | 2838 | 0.030 |
Why?
| | Substrate Specificity | 1 | 1996 | 371 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1996 | 225 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 1996 | 2138 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 1996 | 2894 | 0.030 |
Why?
| | Quality Improvement | 1 | 2021 | 1163 | 0.030 |
Why?
| | Disease-Free Survival | 2 | 2007 | 685 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 1996 | 1350 | 0.020 |
Why?
| | Exsanguination | 1 | 2012 | 19 | 0.020 |
Why?
| | Blood Group Incompatibility | 1 | 2012 | 15 | 0.020 |
Why?
| | Neoplasm Staging | 2 | 2007 | 1371 | 0.020 |
Why?
| | Hypotension | 1 | 2012 | 122 | 0.020 |
Why?
| | Registries | 2 | 2012 | 2015 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 1998 | 1430 | 0.020 |
Why?
| | Platelet Count | 1 | 2011 | 85 | 0.020 |
Why?
| | Inflammation | 3 | 1996 | 2835 | 0.020 |
Why?
| | Blood Coagulation Disorders | 1 | 2012 | 172 | 0.020 |
Why?
| | Shock, Hemorrhagic | 1 | 2012 | 167 | 0.020 |
Why?
| | Adolescent | 3 | 2012 | 21382 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2021 | 2639 | 0.020 |
Why?
| | Models, Biological | 1 | 1996 | 1773 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2000 | 3555 | 0.020 |
Why?
| | Odds Ratio | 1 | 2011 | 1065 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2012 | 642 | 0.020 |
Why?
| | NADPH Oxidases | 2 | 1999 | 113 | 0.020 |
Why?
| | Brain Injuries | 1 | 2012 | 494 | 0.020 |
Why?
| | Career Choice | 1 | 2009 | 216 | 0.020 |
Why?
| | Length of Stay | 1 | 2012 | 1205 | 0.020 |
Why?
| | Lymph Node Excision | 1 | 2007 | 170 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2009 | 7585 | 0.020 |
Why?
| | Logistic Models | 1 | 2011 | 2067 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 2022 | 0.010 |
Why?
| | Cysteine-Rich Protein 61 | 1 | 2005 | 7 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 2005 | 180 | 0.010 |
Why?
| | Antibodies, Neoplasm | 1 | 2005 | 34 | 0.010 |
Why?
| | RNA, Neoplasm | 1 | 2005 | 82 | 0.010 |
Why?
| | Survival Analysis | 1 | 2007 | 1321 | 0.010 |
Why?
| | United States | 1 | 2021 | 14690 | 0.010 |
Why?
| | Ultrasonography, Interventional | 1 | 2005 | 141 | 0.010 |
Why?
| | Extracellular Matrix Proteins | 1 | 2005 | 153 | 0.010 |
Why?
| | Cluster Analysis | 1 | 2005 | 497 | 0.010 |
Why?
| | Age Factors | 1 | 2011 | 3284 | 0.010 |
Why?
| | Mice, Nude | 1 | 2005 | 696 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 975 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2005 | 1733 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 1935 | 0.010 |
Why?
| | Infant | 1 | 2012 | 9395 | 0.010 |
Why?
| | Child, Preschool | 1 | 2012 | 10997 | 0.010 |
Why?
| | Quality of Life | 1 | 2009 | 2878 | 0.010 |
Why?
| | Patient Selection | 1 | 2001 | 690 | 0.010 |
Why?
| | Reactive Oxygen Species | 1 | 1999 | 621 | 0.010 |
Why?
| | Chromatography, Thin Layer | 1 | 1996 | 26 | 0.010 |
Why?
| | Stimulation, Chemical | 1 | 1996 | 59 | 0.010 |
Why?
| | Neutrophil Activation | 1 | 1996 | 80 | 0.010 |
Why?
| | Enzyme Activation | 1 | 1996 | 810 | 0.010 |
Why?
| | Child | 1 | 2012 | 21819 | 0.010 |
Why?
| | Lipids | 1 | 1996 | 665 | 0.010 |
Why?
|
|
Barnett's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|